Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study supports genetic testing for all breast cancer patients age 65 and younger

Key clinical point: Expanding National Comprehensive Cancer Network genetic testing criteria could improve detection of high-risk germline variants.

Major finding: About 30% of women with germline variants in a nine-gene panel would not have met National Comprehensive Cancer Network testing criteria for hereditary breast cancer.

Study details: An analysis of 3,907 women included in a prospective breast cancer registry.

Disclosures: The study was supported by grants from the National Institutes of Health and the Breast Cancer Research Foundation. The authors disclosed relationships with Grail, bioTheranostics, Myriad Genetics, and other companies.


Yadav S et al. J Clin Oncol. 2020 Mar 3. doi: 10.1200/JCO.19.02190.